Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans

PLoS Neglected Tropical Diseases

Volumn 6, Issue 7, 2012, Pages

  Lindow, Janet C ^a   Borochoff Porte, Nathan ^a   Durbin, Anna P ^b   Whitehead, Stephen S ^c   Fimlaid, Kelly A ^a   Bunn, Janice Y ^d   Kirkpatrick, Beth D ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DENGUE VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANEMIA; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE; DENGUE VIRUS 1; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; NORMAL HUMAN; RASH; SEROTYPE; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION; VIREMIA; ADULT; CD4+ T LYMPHOCYTE; DENGUE VIRUS; HUMAN EXPERIMENT; IMMUNOLOGY; METHODOLOGY; SECRETION (PROCESS); TIME;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOKINES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FLOW CYTOMETRY; HUMAN EXPERIMENTATION; HUMANS; TIME FACTORS; VACCINATION;

EID: 84864604405     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001742     Document Type: Article

References (57)

1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7-S16.
2. Morens DM, Fauci AS, (2008) Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 299: 214-216.
3. (2010) Locally acquired Dengue-Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep 59: 577-581.
4. Srikiatkhachorn A, Rothman AL, Gibbons RV, Sittisombut N, Malasit P, et al. (2011) Dengue-how best to classify it. Clin Infect Dis 53: 563-567.
5. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
6. Rothman AL, (2004) Dengue: defining protective versus pathologic immunity. J Clin Invest 113: 946-951.
7. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS, (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444-451.
8. Rothman AL, (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11: 532-543.
9. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, et al. (2003) Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921-927.
10. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2-9.
11. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (1997) Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 176: 322-330.
12. Mathew A, Rothman AL, (2008) Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 225: 300-313.
13. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, et al. (2010) Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 4: e617.
14. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, et al. (2003) Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191-202.
15. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. (2000) Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol 152: 793-799; discussion 804.
16. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, et al. (1990) Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 42: 179-184.
17. Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, et al. (2006) Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg 75: 1113-1117.
18. Cologna R, Armstrong PM, Rico-Hesse R, (2005) Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 79: 853-859.
19. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, et al. (1997) Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230: 244-251.
20. Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, et al. (2006) Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 74: 449-456.
21. Islam MA, Ahmed MU, Begum N, Chowdhury NA, Khan AH, et al. (2006) Molecular characterization and clinical evaluation of dengue outbreak in 2002 in Bangladesh. Jpn J Infect Dis 59: 85-91.
22. Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, et al. (2006) The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2: 167-173.
23. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, et al. (2005) rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191: 710-718.
24. Kurane I, Innis BL, Nisalak A, Hoke C, Nimmannitya S, et al. (1989) Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J Clin Invest 83: 506-513.
25. Mangada MM, Ennis FA, Rothman AL, (2004) Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. J Immunol Methods 284: 89-97.
26. Roederer M, Nozzi JL, Nason MC, (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
27. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et al. (1999) Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179: 755-762.
28. Hober D, Poli L, Roblin B, Gestas P, Chungue E, et al. (1993) Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48: 324-331.
29. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, et al. (1991) Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 88: 1473-1480.
30. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et al. (1999) Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 59: 329-334.
31. Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, et al. (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207: 1421-1433.
32. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
33. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, et al. (2009) Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182: 8047-8055.
34. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
35. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, et al. (2010) Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 84: 4998-5006.
36. CDC (2012) CDC Health Information for International Travel 2012 New York Oxford University Press, Inc.
37. Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, et al. (2011) Cross-Reactivity and Expansion of Dengue-Specific T cells During Acute Primary and Secondary Infections in Humans. Scientific Reports 1.
38. Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, et al. (2011) Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 84: 978-987.
39. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, et al. (2010) Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A 107: 16922-16927.
40. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, et al. (2011) Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 203: 1282-1291.
41. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, et al. (2011) A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29: 3895-3904.
42. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
43. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
44. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204: 1405-1416.
45. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A, (2002) Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 169: 6376-6385.
46. Harari A, Petitpierre S, Vallelian F, Pantaleo G, (2004) Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103: 966-972.
47. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909-1922.
48. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, et al. (2005) HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 102: 7239-7244.
49. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, et al. (2002) Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185: 1213-1221.
50. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, et al. (1999) Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186.
51. Minai Y, Hisatsune T, Nishijima KI, Enomoto A, Kaminogawa S, (1994) Activation Via Tcr or Il-2 Receptor of a Cd8+ Suppressor T-Cell Clone- Effect on Il-10 Production and on Proliferation of the Suppressor T-Cell. Cytotechnology 14: 81-87.
52. Yssel H, Malefyt RD, Roncarolo MG, Abrams JS, Lahesmaa R, et al. (1992) Il-10 Is Produced by Subsets of Human Cd4+ T-Cell Clones and Peripheral-Blood T-Cells. Journal of Immunology 149: 2378-2384.
53. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M, (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine & Growth Factor Reviews 15: 61-76.
54. Friberg H, Burns L, Woda M, Kalayanarooj S, Endy TP, et al. (2011) Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol 89: 122-129.
55. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182: 4865-4873.
56. Beaumier CM, Jaiswal S, West KY, Friberg H, Mathew A, et al. (2010) Differential in vivo clearance and response to secondary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells. Viral Immunol 23: 477-485.
57. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, et al. (1996) Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 98: 1684-1691.